UK Markets close in 3 hrs 45 mins

Hutchison China MediTech Limited (HCM.L)

LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
161.23-5.77 (-3.46%)
As of 11:48AM BST. Market open.
Full screen
Previous close167.00
Open162.60
Bid161.20 x 0
Ask164.60 x 0
Day's range160.00 - 164.98
52-week range137.80 - 556.00
Volume13,355
Avg. volume153,695
Market cap1.394B
Beta (5Y monthly)0.50
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    HUTCHMED Highlights Phase III FRESCO-2 MRCT Data Summary of Fruquintinib in Refractory Metastatic Colorectal Cancer from the Upcoming ESMO 2022 Presentation

    — Fruquintinib treatment reduced the risk of death by 34% in metastatic colorectal cancer (0.66 HR) — — Increased disease control with risk of disease progression or death reduced by 68% (0.32 HR) — — Results to be presented in a late-breaking, proffered paper presentation at ESMO — — Conference call and webcast to be held on Monday, September 12 at 2:00 pm Paris time to discuss the full trial results and the unmet medical need in colorectal cancer — HONG KONG and SHANGHAI and FLORHAM PARK, N.J.

  • Globe Newswire

    HUTCHMED Highlights Fruquintinib MRCT FRESCO-2 Data to be Presented at the Upcoming ESMO Congress 2022

    — Trial met primary endpoint of overall survival and all secondary endpoints — — Selected as a late-breaker presentation — — Conference call and webcast to be held on Monday, September 12 at 2:00 pm Paris time to review the presentation at the Congress — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 23, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that initial results of the multi-regional clinical trial (“MRCT”) of fruquintinib

  • Globe Newswire

    Inmagene and HUTCHMED Announce First Participant in Global Phase I Trial of IMG-004

    SAN DIEGO and SHANGHAI, China and HONG KONG, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Inmagene Biopharmaceuticals ("Inmagene") and HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) announce today that the first participant, based in the United States, was dosed in a global Phase I trial of IMG-004, a non-covalent, reversible, third-generation Bruton Tyrosine Kinase (“BTK”) inhibitor. Inmagene is developing the drug candidate to potentially treat immunological diseases. The Phase I study